156 related articles for article (PubMed ID: 11737892)
1. Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment.
Hurst HC
Breast Cancer Res; 2001; 3(6):395-8. PubMed ID: 11737892
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
3. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells.
Delacroix L; Begon D; Chatel G; Jackers P; Winkler R
DNA Cell Biol; 2005 Sep; 24(9):582-94. PubMed ID: 16153159
[TBL] [Abstract][Full Text] [Related]
4. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members.
Olayioye MA
Breast Cancer Res; 2001; 3(6):385-9. PubMed ID: 11737890
[TBL] [Abstract][Full Text] [Related]
5. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers.
Vernimmen D; Gueders M; Pisvin S; Delvenne P; Winkler R
Br J Cancer; 2003 Sep; 89(5):899-906. PubMed ID: 12942124
[TBL] [Abstract][Full Text] [Related]
6. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
Menendez JA; Papadimitropoulou A; Vellon L; Lupu R
Eur J Cancer; 2006 Oct; 42(15):2425-32. PubMed ID: 16406575
[TBL] [Abstract][Full Text] [Related]
7. A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells.
Hua G; Zhu B; Rosa F; Deblon N; Adélaïde J; Kahn-Perlès B; Birnbaum D; Imbert J
Mol Cancer Res; 2009 Mar; 7(3):402-14. PubMed ID: 19276186
[TBL] [Abstract][Full Text] [Related]
8. Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC; Zhang L; Hortobagyi GN; Hung MC
Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
[TBL] [Abstract][Full Text] [Related]
9. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.
Nagy P; Jenei A; Damjanovich S; Jovin TM; Szölôsi J
Pathol Oncol Res; 1999; 5(4):255-71. PubMed ID: 10607920
[TBL] [Abstract][Full Text] [Related]
10. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
[TBL] [Abstract][Full Text] [Related]
11. Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer.
Wolfson E; Goldenberg M; Solomon S; Frishberg A; Pinkas-Kramarski R
Oncotarget; 2016 Oct; 7(40):65320-65334. PubMed ID: 27542246
[TBL] [Abstract][Full Text] [Related]
12. The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression.
Eckel KL; Tentler JJ; Cappetta GJ; Diamond SE; Gutierrez-Hartmann A
DNA Cell Biol; 2003 Feb; 22(2):79-94. PubMed ID: 12713734
[TBL] [Abstract][Full Text] [Related]
13. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
14. Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell.
Choi HK; Yang JW; Kang KW
Cancer Lett; 2006 Oct; 242(2):198-206. PubMed ID: 16488535
[TBL] [Abstract][Full Text] [Related]
15. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis.
Chang CH; Scott GK; Kuo WL; Xiong X; Suzdaltseva Y; Park JW; Sayre P; Erny K; Collins C; Gray JW; Benz CC
Oncogene; 1997 Apr; 14(13):1617-22. PubMed ID: 9129154
[TBL] [Abstract][Full Text] [Related]
16. ErbB2 activation of ESX gene expression.
Neve RM; Ylstra B; Chang CH; Albertson DG; Benz CC
Oncogene; 2002 May; 21(24):3934-8. PubMed ID: 12032832
[TBL] [Abstract][Full Text] [Related]
17. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu and topoisomerase IIalpha in breast cancer.
Järvinen TA; Liu ET
Breast Cancer Res Treat; 2003 Apr; 78(3):299-311. PubMed ID: 12755489
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.
Zhao YH; Zhou M; Liu H; Ding Y; Khong HT; Yu D; Fodstad O; Tan M
Oncogene; 2009 Oct; 28(42):3689-701. PubMed ID: 19668225
[TBL] [Abstract][Full Text] [Related]
20. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]